Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2014

Grohar Patrick J, Segars Laure E, Yeung Choh, Pommier Yves, D'Incalci Maurizio, Mendoza Arnulfo, Helman Lee J

Abstract excerpt

PURPOSE: The goal of this study is to optimize the activity of trabectedin for Ewing sarcoma by developing a molecularly targeted combination therapy. EXPERIMENTAL DESIGN: We have recently shown that trabectedin interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. In this report, we build on this work to develop a trabectedin-based combination therapy with improved EWS-FLI1 suppression that also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Dioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Proto-Oncogene Protein c-fli-1

Share to RecQ Helicases

Share to RNA-Binding Protein EWS

Share to Sarcoma, Ewing

Share to Werner Syndrome Helicase

Source

Open in PubMed Open full text

Identifiers

PMID: 24277455
DOI: 10.1158/1078-0432.CCR-13-0901
PMCID: PMC5510643

Genes

FLI1
WRN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.PMID 24277455Read ↗

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the NucleusSemantic proximity Read ↗

Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcriptionSemantic proximity Read ↗

A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcomaSemantic proximity Read ↗

Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing SarcomaSemantic proximity Read ↗

Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput ScreeningSemantic proximity Read ↗

Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma CellsSemantic proximity Read ↗

Efficacy of ATR inhibitors as single agents in Ewing sarcomaSemantic proximity Read ↗

CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1–Dependent IGF-1 SignalingSemantic proximity Read ↗

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcomaSemantic proximity Read ↗

Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing SarcomaSemantic proximity Read ↗

Drug-mediated inhibition of Fli-1 for the treatment of leukemiaSemantic proximity Read ↗

Targeted Therapy of Ewing's SarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.